Longevity of the Placebo Effect in the Therapeutic Angiogenesis and Laser Myocardial Revascularization Trials in Patients With Coronary Heart Disease

This publication has 12 references indexed in Scilit:

• Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein
  The Journal of Thoracic and Cardiovascular Surgery, 2002
• Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial
  The Lancet, 2002
• Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2
  Circulation, 2002
• Magnetic resonance imaging demonstrates improved regional systolic wall motion and thickening and myocardial perfusion of myocardial territories treated by laser myocardial revascularization
  Journal of the American College of Cardiology, 2001
• Pharmacokinetics and Pharmacodynamics of Recombinant FGF‐2 in a Phase I Trial in Coronary Artery Disease
  The Journal of Clinical Pharmacology, 2001
• Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a Phase I open-label dose escalation study
  Journal of the American College of Cardiology, 2000
• Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease.
  Circulation, 2000
• Short- and Intermediate-Term Clinical Outcomes From Direct Myocardial Laser Revascularization Guided by Biosense Left Ventricular Electromechanical Mapping
  Circulation, 2000
• Local Perivascular Delivery of Basic Fibroblast Growth Factor in Patients Undergoing Coronary Bypass Surgery
  Circulation, 1999
• Comparison of Three Quality of Life Instruments in Stable Angina Pectoris: Seattle Angina Questionnaire, Short Form Health Survey (SF-36), and Quality of Life Index-Cardiac Version III
  Journal of Clinical Epidemiology, 1998